Company news

On September, 2-4 representatives of Isotope JSC took part in the second Russian-Italian scientific conference "Challenges of oncology in the era of COVID-19 ", held in a hybrid format in Taranto (Italy).

ROSATOM took part in the international online conference Nuclear Trade and Technology Exchange (NT2E), organized by the Brazilian Association for the Development of Nuclear Activities (ABDAN) on July 27-29, 2021.

Isotope JSC (a part of Rusatom Healthcare JSC, Rosatom’s radiation technologies integrator) has signed a five-year contract with Brazil’s Nuclear and Energy Research Institute (IPEN; linked to the National Nuclear Energy Commission or CNEN) to supply lutetium-177 and actinium-225, the most promising medical isotopes in Radiopharma.

In 2020, revenue from sales of stable isotopes manufactured by Electrochemical Plant JSC (an enterprise of ROSATOM’s TVEL Fuel Company in Zelenogorsk, Krasnoyarsk region) increased by 14% year on year, exceeding 1.5 billion rubles for the first time.

Isotope JSC, official distributor of isotope products manufactured by ROSATOM’s enterprises, successfully delivered lutetium-177 produced according to EU GMP standards to Nuclear Medicine Department of Policlinico of Bari (Apulia, Italy) for quality evaluation. The activity was implemented within the scope of the Healthcare Memorandum of Understanding signed between Apulia Region and ROSATOM in November 2019.

Come to see us at our virtual booth!

Rio de Janeiro, September 8. ROSATOM took part in the 34th Annual Brazilian Congress of Nuclear Medicine, a key event in the country's nuclear medicine which closed Monday, September 7.

August 20, Moscow - ROSATOM has switched to using a united brand. While preserving their names and unique identity, organizations of the Russian nuclear industry will get unified logos based on the trademark of ROSATOM - the Mobius strip. Such approach to corporate branding is called “umbrella branding,” and many top-class global corporations are using it.

In 2018, an Italian, Roberto La Forgia came to work in Russia joining JSC Isotope team to become the only foreigner in ROSATOM’s nuclear medicine business.

On February 20th, 2020, Kushnarev Maxim Sergeevich was appointed to the position of JSC Isotope General Director.